NASDAQ:CERC

Cerecor Competitors

$2.58
-0.03 (-1.15 %)
(As of 04/14/2021 05:20 PM ET)
Add
Compare
Today's Range
$2.56
Now: $2.58
$2.78
50-Day Range
$2.72
MA: $3.20
$4.05
52-Week Range
$1.97
Now: $2.58
$4.50
Volume461,628 shs
Average Volume964,006 shs
Market Capitalization$229.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67

Competitors

Cerecor (NASDAQ:CERC) Vs. AKRO, EPIX, VNDA, RDUS, ANNX, and AFMD

Should you be buying CERC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cerecor, including Akero Therapeutics (AKRO), ESSA Pharma (EPIX), Vanda Pharmaceuticals (VNDA), Radius Health (RDUS), Annexon (ANNX), and Affimed (AFMD).

Akero Therapeutics (NASDAQ:AKRO) and Cerecor (NASDAQ:CERC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Risk & Volatility

Akero Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Akero Therapeutics and Cerecor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akero Therapeutics00703.00
Cerecor00303.00

Akero Therapeutics currently has a consensus price target of $57.2857, suggesting a potential upside of 110.07%. Cerecor has a consensus price target of $9.50, suggesting a potential upside of 268.22%. Given Cerecor's higher probable upside, analysts clearly believe Cerecor is more favorable than Akero Therapeutics.

Valuation & Earnings

This table compares Akero Therapeutics and Cerecor's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.42
Cerecor$6.75 million34.06$-16,070,000.00($0.30)-8.60

Cerecor has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Cerecor, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akero Therapeutics and Cerecor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akero TherapeuticsN/A-40.84%-38.33%
Cerecor-799.40%-93.78%-61.01%

Institutional & Insider Ownership

83.5% of Akero Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Cerecor shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 58.0% of Cerecor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cerecor beats Akero Therapeutics on 7 of the 12 factors compared between the two stocks.

Cerecor (NASDAQ:CERC) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Risk & Volatility

Cerecor has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500.

Institutional and Insider Ownership

66.4% of Cerecor shares are held by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are held by institutional investors. 58.0% of Cerecor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Cerecor and ESSA Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerecor$6.75 million34.06$-16,070,000.00($0.30)-8.60
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-25.62

Cerecor has higher revenue and earnings than ESSA Pharma. ESSA Pharma is trading at a lower price-to-earnings ratio than Cerecor, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cerecor and ESSA Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerecor-799.40%-93.78%-61.01%
ESSA PharmaN/A-46.31%-45.08%

Analyst Ratings

This is a summary of recent recommendations for Cerecor and ESSA Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerecor00303.00
ESSA Pharma00503.00

Cerecor presently has a consensus target price of $9.50, suggesting a potential upside of 268.22%. ESSA Pharma has a consensus target price of $28.80, suggesting a potential upside of 8.64%. Given Cerecor's higher probable upside, equities research analysts plainly believe Cerecor is more favorable than ESSA Pharma.

Summary

Cerecor beats ESSA Pharma on 7 of the 12 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Cerecor (NASDAQ:CERC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Vanda Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vanda Pharmaceuticals and Cerecor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$227.19 million3.97$115.55 million$2.117.80
Cerecor$6.75 million34.06$-16,070,000.00($0.30)-8.60

Vanda Pharmaceuticals has higher revenue and earnings than Cerecor. Cerecor is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vanda Pharmaceuticals and Cerecor, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vanda Pharmaceuticals04102.20
Cerecor00303.00

Vanda Pharmaceuticals currently has a consensus price target of $15.40, suggesting a potential downside of 6.33%. Cerecor has a consensus price target of $9.50, suggesting a potential upside of 268.22%. Given Cerecor's stronger consensus rating and higher probable upside, analysts clearly believe Cerecor is more favorable than Vanda Pharmaceuticals.

Institutional & Insider Ownership

97.6% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 66.4% of Cerecor shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 58.0% of Cerecor shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vanda Pharmaceuticals and Cerecor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vanda Pharmaceuticals8.02%4.56%3.88%
Cerecor-799.40%-93.78%-61.01%

Summary

Vanda Pharmaceuticals beats Cerecor on 8 of the 14 factors compared between the two stocks.

Radius Health (NASDAQ:RDUS) and Cerecor (NASDAQ:CERC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Institutional & Insider Ownership

66.4% of Cerecor shares are owned by institutional investors. 2.9% of Radius Health shares are owned by company insiders. Comparatively, 58.0% of Cerecor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Radius Health and Cerecor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Radius Health06302.33
Cerecor00303.00

Radius Health presently has a consensus target price of $24.60, suggesting a potential upside of 25.45%. Cerecor has a consensus target price of $9.50, suggesting a potential upside of 268.22%. Given Cerecor's stronger consensus rating and higher possible upside, analysts clearly believe Cerecor is more favorable than Radius Health.

Profitability

This table compares Radius Health and Cerecor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Radius Health-48.61%N/A-56.85%
Cerecor-799.40%-93.78%-61.01%

Volatility and Risk

Radius Health has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Valuation and Earnings

This table compares Radius Health and Cerecor's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Radius Health$173.32 million5.32$-132,990,000.00($2.89)-6.81
Cerecor$6.75 million34.06$-16,070,000.00($0.30)-8.60

Cerecor has lower revenue, but higher earnings than Radius Health. Cerecor is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Summary

Cerecor beats Radius Health on 8 of the 13 factors compared between the two stocks.

Cerecor (NASDAQ:CERC) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Profitability

This table compares Cerecor and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerecor-799.40%-93.78%-61.01%
AnnexonN/A-566.22%-32.99%

Analyst Ratings

This is a breakdown of current ratings for Cerecor and Annexon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerecor00303.00
Annexon00503.00

Cerecor presently has a consensus price target of $9.50, indicating a potential upside of 268.22%. Annexon has a consensus price target of $34.3333, indicating a potential upside of 47.80%. Given Cerecor's higher probable upside, equities analysts plainly believe Cerecor is more favorable than Annexon.

Insider & Institutional Ownership

66.4% of Cerecor shares are owned by institutional investors. Comparatively, 91.2% of Annexon shares are owned by institutional investors. 58.0% of Cerecor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Cerecor and Annexon's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerecor$6.75 million34.06$-16,070,000.00($0.30)-8.60
AnnexonN/AN/A$-37,180,000.00N/AN/A

Cerecor has higher revenue and earnings than Annexon.

Summary

Cerecor beats Annexon on 5 of the 9 factors compared between the two stocks.

Cerecor (NASDAQ:CERC) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cerecor and Affimed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerecor00303.00
Affimed00503.00

Cerecor currently has a consensus price target of $9.50, indicating a potential upside of 268.22%. Affimed has a consensus price target of $13.80, indicating a potential upside of 33.59%. Given Cerecor's higher probable upside, research analysts clearly believe Cerecor is more favorable than Affimed.

Volatility and Risk

Cerecor has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.81, suggesting that its share price is 181% more volatile than the S&P 500.

Insider and Institutional Ownership

66.4% of Cerecor shares are owned by institutional investors. Comparatively, 52.3% of Affimed shares are owned by institutional investors. 58.0% of Cerecor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cerecor and Affimed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerecor-799.40%-93.78%-61.01%
Affimed-172.01%-99.24%-37.40%

Earnings and Valuation

This table compares Cerecor and Affimed's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerecor$6.75 million34.06$-16,070,000.00($0.30)-8.60
Affimed$23.96 million38.08$-36,250,000.00($0.56)-18.45

Cerecor has higher earnings, but lower revenue than Affimed. Affimed is trading at a lower price-to-earnings ratio than Cerecor, indicating that it is currently the more affordable of the two stocks.

Summary

Cerecor beats Affimed on 7 of the 13 factors compared between the two stocks.


Cerecor Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.31-3.3%$918.28 millionN/A-12.59Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$26.64-1.7%$914.76 millionN/A-24.67
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.45-0.9%$895.14 million$227.19 million45.70
Radius Health logo
RDUS
Radius Health
1.3$19.67-3.9%$886.30 million$173.32 million-8.06Gap Down
Annexon logo
ANNX
Annexon
1.9$23.35-1.3%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.33-4.3%$873.54 million$23.96 million-17.51Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.16-1.5%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.22-2.5%$863.20 million$31.13 million-7.56Analyst Report
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-1.5%$845.56 millionN/A-10.37
Epizyme logo
EPZM
Epizyme
1.8$8.22-0.4%$833.11 million$23.80 million-3.69
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.40-0.4%$822.01 million$322.36 million124.29
Humanigen logo
HGEN
Humanigen
1.7$15.38-1.1%$813.46 millionN/A0.00Analyst Report
Increase in Short Interest
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$24.02-4.6%$806.52 million$296.70 million49.02Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.29-7.4%$781.24 millionN/A0.00Increase in Short Interest
Ardelyx logo
ARDX
Ardelyx
1.6$7.84-8.2%$773.65 million$5.28 million-7.76Unusual Options Activity
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.20-1.0%$765.62 million$40.89 million-3.52Analyst Report
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$27.15-3.5%$758.65 million$148.36 million-7.05News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.19-0.2%$749.20 million$322.07 million-4.94Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.45-2.0%$727.39 million$150,000.00-4.93
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.89-1.4%$723.91 million$2.22 million-17.00
Chimerix logo
CMRX
Chimerix
1.3$8.37-0.7%$711.99 million$12.52 million-14.68Analyst Report
Increase in Short Interest
Veru logo
VERU
Veru
1.4$9.88-0.5%$706.90 million$42.59 million-35.28Analyst Report
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$21.41-1.1%$698.95 million$252 million-2.19News Coverage
OrganiGram logo
OGI
OrganiGram
1.6$2.60-11.9%$677.07 million$64.61 million-3.82Earnings Announcement
Analyst Report
Decrease in Short Interest
News Coverage
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.96-2.2%$676.77 million$13.80 million-14.47Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.95-0.9%$667.23 million$19.56 million-19.39
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.15-11.7%$664.02 millionN/A-4.48Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.53-1.4%$653.32 millionN/A-2.40Increase in Short Interest
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.25-1.8%$653.31 million$143.01 million-1.19
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.48-7.0%$648.86 million$6.83 million-20.08News Coverage
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.73-3.2%$634.55 million$59.29 million-24.87Increase in Short Interest
News Coverage
Gap Up
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.39-0.6%$622.54 million$9.64 million-5.28News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.90-7.2%$621.98 million$5.09 million-6.50Analyst Downgrade
News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.92-4.9%$605.76 million$12.69 million-11.98Increase in Short Interest
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$36.77-2.2%$602.22 millionN/A-17.02
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.80-0.8%$589.46 million$17.26 million-3.83Analyst Revision
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.79-3.6%$584.23 millionN/A-9.99Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.27-3.6%$561.28 million$8 million-7.85
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$43.37-2.9%$556.83 million$195.89 million123.92
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.64-3.4%$547.56 millionN/A-5.42Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.85-4.6%$543.18 millionN/A-4.28
Inventiva logo
IVA
Inventiva
0.0$13.60-2.9%$540.43 millionN/A0.00News Coverage
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$6.99-0.6%$539.54 million$26.74 million17.48
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.75-3.3%$536.73 millionN/A-9.11Increase in Short Interest
News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.42-2.4%$529.13 million$1.19 million-6.84
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.01-4.0%$520.28 millionN/A-4.77
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.98-2.6%$519.55 millionN/A-5.63
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.15-0.5%$516.80 million$25 million-18.69Analyst Report
Evolus logo
EOLS
Evolus
1.3$11.72-0.5%$509.93 million$34.92 million-5.77Analyst Report
Gap Up
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.